Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Infection with HCV genotype 1, 4, 5, or 6
Cirrhosis determination
Subject met the following classifications:
* Treatment-naive
* Screening laboratory values within defined thresholds
* Not treated with any investigational drug or device within 30 days of screening
Use of highly effective contraception methods if female of childbearing potential or sexually active male
You may not be if
Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase
Pregnant or nursing female, or male with pregnant female partner
Current or prior history of clinical hepatic decompensation
History of clinically-significant illness or any other major medical disorder that may have interfered with subject treatment, assessment, or compliance with the protocol
Excessive alcohol ingestion or significant drug abuse
Clareo Health | Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
